{"id":30831,"date":"2022-06-17T14:49:20","date_gmt":"2022-06-17T12:49:20","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=30831"},"modified":"2022-06-17T14:49:09","modified_gmt":"2022-06-17T12:49:09","slug":"un-nou-tractament-contra-el-glioblastoma-ofereix-resultats-prometedors","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/un-nou-tractament-contra-el-glioblastoma-ofereix-resultats-prometedors\/","title":{"rendered":"Un nou tractament contra el glioblastoma ofereix resultats prometedors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Un <a rel=\"noreferrer noopener\" href=\"https:\/\/www.imim.cat\/noticies\/1081\/seguretat-i-eficacia-duna-nova-combinacio-de-tractaments-per-als-glioblastomes\" target=\"_blank\">estudi col\u00b7laboratiu<\/a> que ha comptat amb la participaci\u00f3 de Mar\u00eda Mart\u00ednez, de l&#8217;<a rel=\"noreferrer noopener\" href=\"http:\/\/www.imim.es\/\" target=\"_blank\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques&nbsp;(IMIM)<\/a>, ha aconseguit <strong>resultats prometedors a la <a href=\"https:\/\/ellipse.prbb.org\/ca\/assaigs-clinics-el-llarg-cami-del-desenvolupament-de-nous-farmacs\/\" target=\"_blank\" rel=\"noreferrer noopener\">fase I de desenvolupament d&#8217;un nou tractament<\/a> per al glioblastoma<\/strong>. Es tracta de la <strong>combinaci\u00f3 del f\u00e0rmac crizotinib amb radioter\u00e0pia i temozolomida<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El glioblastoma \u00e9s un tipus de<strong> tumor que afecta les c\u00e8l\u00b7lules de la glia, les encarregades de donar suport al teixit cerebral<\/strong>. \u00c9s el <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/el-major-estudi-fins-ara-no-troba-relacio-causal-entre-lus-del-mobil-i-els-tumors-cerebrals\/\" target=\"_blank\">tumor cerebral<\/a> <strong>primari m\u00e9s habitual en adults i un dels m\u00e9s agressius<\/strong>. Per aix\u00f2, Mart\u00ednez recalca que \u00ab\u00e9s de <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/iris-lioba-matilla-vaz-imim-sense-assaigs-clinics-la-medicina-no-podria-avancar\/\" target=\"_blank\">gran import\u00e0ncia fer estudis cl\u00ednics<\/a> en aquest tipus de tumor ja que actualment hi ha poques alternatives terap\u00e8utiques\u00bb.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Despr\u00e9s d&#8217;analitzar l&#8217;efic\u00e0cia i la seguretat d&#8217;aquesta combinaci\u00f3 de f\u00e0rmacs, els resultats han demostrat un <strong>augment en el per\u00edode de superviv\u00e8ncia sense progressi\u00f3<\/strong>. Aquest fa refer\u00e8ncia al temps que el o la pacient conviu amb la malaltia sense empitjorar, fet que suposa un <strong>augment de la seva esperan\u00e7a de vida<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El seg\u00fcent pas ser\u00e0 confirmar les conclusions obtingudes, per a la qual cosa caldr\u00e0 fer m\u00e9s estudis. I, precisament aqu\u00ed, Mart\u00ednez destaca la rellev\u00e0ncia de les <strong>investigacions col\u00b7laboratives entre grups de recerca precl\u00ednics i equips cl\u00ednics<\/strong> per poder portar aquests aven\u00e7os als pacients.<\/p>\n\n\n\n<div style=\"height:66px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;IMIM ha participat en un estudi que analitza l&#8217;efic\u00e0cia i la seguretat d&#8217;una nova combinaci\u00f3 de f\u00e0rmacs contra el glioblastoma.<\/p>\n","protected":false},"author":28,"featured_media":30815,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[312,263,213,757],"new-type":[35],"class_list":["post-30831","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-cancer-ca","tag-cervell","tag-imim","tag-tractament","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/30831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=30831"}],"version-history":[{"count":9,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/30831\/revisions"}],"predecessor-version":[{"id":30854,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/30831\/revisions\/30854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/30815"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=30831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=30831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=30831"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=30831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}